靶向治疗与免疫治疗在放射性碘难治性分化型甲状腺癌中的应用与前景

林秋玉; 王宇鑫; 林承赫

doi:10.19401/j.cnki.1007-3639.2025.01.007

您当前的位置：

首页 >

文章列表页 >

靶向治疗与免疫治疗在放射性碘难治性分化型甲状腺癌中的应用与前景

专家述评 | 更新时间：2025-12-31

- 靶向治疗与免疫治疗在放射性碘难治性分化型甲状腺癌中的应用与前景
- Application and prospect of targeted therapy and immunotherapy in radioiodine-refractory differentiated thyroid cancer
- 中国癌症杂志 2025年35卷第1期页码：58-67
- 作者机构：
  
  吉林大学第一医院核医学科，吉林长春 130012
- 作者简介：
  
  [ "林秋玉（ORCID: 0000-0002-6925-184X），博士，副主任医师、副教授。" ]
  [ "林承赫，主任医师，教授，博士研究生导师，吉林大学第一医院核医学科主任。中国临床肿瘤学会核医学专家委员会副主任委员，中国临床肿瘤学会甲状腺癌专家委员会常委，中华医学会核医学分会委员兼治疗学组副组长，中国医师协会核医学医师分会理事，中国核学会核医学分会理事，中国抗癌协会肿瘤核医学专业委员会常委。《中华核医学与分子影像杂志》编委，《中国临床医学影像杂志》常务编委。" ]
- 基金信息：
  
  国家自然科学基金青年基金(81901774)
- DOI：10.19401/j.cnki.1007-3639.2025.01.007
  中图分类号： R736.1
- 收稿：2024-12-13，
  
  修回：2025-01-21，
  
  纸质出版：2025-01-30
- 稿件说明：
移动端阅览
林秋玉, 王宇鑫, 林承赫. 靶向治疗与免疫治疗在放射性碘难治性分化型甲状腺癌中的应用与前景[J]. 中国癌症杂志, 2025,35(1):58-67.

Qiuyu LIN, Yuxin WANG, Chenghe LIN. Application and prospect of targeted therapy and immunotherapy in radioiodine-refractory differentiated thyroid cancer[J]. China Oncology, 2025, 35(1): 58-67.
林秋玉, 王宇鑫, 林承赫. 靶向治疗与免疫治疗在放射性碘难治性分化型甲状腺癌中的应用与前景[J]. 中国癌症杂志, 2025,35(1):58-67. DOI： 10.19401/j.cnki.1007-3639.2025.01.007.

Qiuyu LIN, Yuxin WANG, Chenghe LIN. Application and prospect of targeted therapy and immunotherapy in radioiodine-refractory differentiated thyroid cancer[J]. China Oncology, 2025, 35(1): 58-67. DOI： 10.19401/j.cnki.1007-3639.2025.01.007.

摘要

甲状腺癌（thyroid cancer，TC）是一种常见的内分泌系统恶性肿瘤，其中分化型TC（differentiated TC，DTC）占90%以上，通常大多数患者在接受放射性碘（radioactive iodine，RAI）治疗后总体预后良好，但仍有部分患者的病灶在治疗过程中逐渐丧失摄碘能力，成为RAI难治性DTC（radioiodine-refractory DTC，RAIR-DTC），预后较差。对于无法手术切除的RAIR-DTC复发病灶或远处转移灶，既往认为治疗方式有限。随着对RAIR-DTC的发生机制及其生物分子层面的改变有了更深的认识，靶向治疗、免疫治疗及靶向治疗联合免疫治疗呈现出广阔的应用前景，其有效性和安全性也在人类研究中被证实，为RAIR-DTC治疗带来新的希望。本文概括了RAIR-DTC的发生、发展机制、靶向治疗与免疫治疗的临床研究现状及其主要结论，以期为今后的研究提供方向。多激酶抑制剂（multiple kinase inhibitors，MKIs）是晚期转移性RAIR-DTC的一线治疗方案。目前被美国食品药品管理局（Food and Drug Administration，FDA）批准用于治疗RAIR-DTC的药物包括索拉非尼（sorafenib）、仑伐替尼（lenvatinib）、卡博替尼（cabozantinib），前两者也被中国国家药品监督管理局批准用于RAIR-DTC的治疗。中国还有安罗替尼（anlotinib）、多纳非尼（donafenib）被批准用于RAIR-DTC的治疗。以上靶向药物的有效性和安全性均得到了验证。阿帕替尼（apatinib）是一种中国自主研发的血管生成抑制剂，有望成为sorafenib耐药时有效的挽救治疗方法。而单靶点选择性抑制剂因作用靶点单一，不良反应通常较轻。对于某些含有特定突变类型的RAIR-DTC，单靶点选择性抑制剂可以更好地发挥效果。TC通常被认为肿瘤突变负荷（tumor mutation burden，TMB）较低，既往认为免疫治疗的效果有限。包括帕博利珠单抗（pembrolizumab）、度伐利尤单抗（durvalumab）、阿特珠单抗（atezolizumab）、伊匹单抗（ipilimumab）在内的免疫检查点抑制剂，单独使用时疗效常不理想。当联合靶向治疗时，pembrolizumab可以增强靶向药物的疗效，可作为一种可行的挽救疗法，这可能与靶向治疗联合免疫治疗的“协同效应”有关。对于联合治疗，各种治疗分别对抑制肿瘤、延长患者生存期发挥了多大作用需要明确，特别是在病例数较少的情况下，如何设计合理的对照成为关键。既往研究受限于RAIR-DTC定义模糊、纳入患者量少且异质性大，未来需要开展前瞻性、多中心、大规模的临床试验。同时，还需要考虑治疗后延长的无进展生存期（progression-free survival，PFS）是否能转化为长期生存获益，以及是否能改善患者的生活质量。总之，RAIR-DTC的治疗仍面临诸多挑战，未来需要在这些方面不断探索和研究。

Abstract

Thyroid cancer (TC) is a common malignant tumor of the endocrine system

with differentiated TC (DTC) accounting for more than 90%. Most patients usually have a good overall prognosis after receiving radioactive iodine (RAI) treatment

however some patients’ lesions gradually lose the ability to take up iodine during treatment and become RAI-refractory DTC (RAIR-DTC)

with a poor prognosis. For RAIR-DTC recurrence lesions or distant metastases that cannot be surgically removed

it was previously believed that there were limited treatment options. With a deeper understanding of the pathogenesis of RAIR-DTC and its changes at the biomolecular level

targeted therapy

immunotherapy and combined targeted and immune therapy have shown broad application prospects. Their effectiveness and safety have also been confirmed in human studies

bringing new hope for the treatment of RAIR-DTC. This article summarized the pathogenesis and development mechanism of RAIR-DTC

the current status of clinical research on targeted therapy and immunotherapy

and their main conclusions

in order to provide direction for future research. Multi-kinase inhibitors (MKIs) are the first-line therapy for advanced metastatic RAIR-DTC. Currently

Food and Drug Administration (FDA) of the United States has approved the following drugs for the treatment of RAIR-DTC: sorafenib

lenvatinib and cabozantinib. The first two of these have been approved by China National Medical Products Administration for RAIR-DTC treatment. In China

anlotinib and donafenib have also been approved for RAIR-DTC treatment. The efficacy and safety of these targeted therapies have been verified. Apatinib

an anti-angiogenesis inhibitor independently developed in China

is expected to be an effective salvage therapy for sorafenib-resistant lesions. Selective single-target inhibitors

with their more specific action targets

generally cause fewer side effects. For certain RAIR-DTC patients with specific mutation types

selective single-target inhibitors may be more effective. TC is generally considered to have a low tumor mutational burden (TMB)

and its response to immunotherapy was once thought to be limited. Immune checkpoint inhibitors (ICIs)

including pembrolizumab

durvalumab

atezolizumab and ipilimumab

have shown limited efficacy when used alone. However

when combined with targeted therapy

pembrolizumab can enhance the efficacy of targeted drugs

serving as a viable salvage therapy

potentially due to the “synergistic effect” of the combination therapy. It is crucial to determine the individual contributions of each therapy to tumor suppression and survival extension

especially when the sample size is limited. The design of reasonable controls becomes the key in these studies. Previous studies were obstructed by the unclear definition of RAIR-DTC

limited sample sizes and high heterogeneity. Therefore

prospective

multi-center

large-scale clinical trials are needed in the future. Additionally

it is essential to consider whether prolonged progression-free survival (PFS) after treatment can be translated into long-term survival benefits

and whether it improves the quality of life for patients. In conclusion

the treatment of RAIR-DTC still faces many challenges

we must continue to explore and address these issues in the future.

关键词

Keywords

references

SIEGEL R L , MILLER K D , FUCHS H E , et al. Cancer statistics, 2022 [J ] . CA Cancer J Clin , 2022 , 72 ( 1 ): 7 - 33 .

MAO Y S , XING M Z . Recent incidences and differential trends of thyroid cancer in the USA [J ] . Endocr Relat Cancer , 2016 , 23 ( 4 ): 313 - 322 .

HAUGEN B R , ALEXANDER E K , BIBLE K C , et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer [J ] . Thyroid , 2016, 26 ( 1 ): 1 - 133 .

中国临床肿瘤学会核医学专家委员会 , 中国临床肿瘤学会甲状腺癌专家委员会 , 中华医学会核医学分会 , 等 . 放射性碘难治性分化型甲状腺癌诊治管理指南(2024版) [J ] . 中华核医学与分子影像杂志 , 2024 , 44 ( 6 ): 359 - 372 .

Nuclear Medicine Expert Committee of Chinese Society of Clinical Oncology, Thyroid Cancer Expert Committee of Chinese Society of Clinical Oncology , Thyroid Cancer Expert Committee of Chinese Society of Clinical Oncology, Chinese Society of Nuclear Medicine , et al. Management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2024 edition) [J ] . Chin J Nucl Med Mol Imag , 2024 , 44 ( 6 ): 359 - 372 .

VAN NOSTRAND D , VEYTSMAN I , KULKARNI K , et al. Redifferentiation of differentiated thyroid cancer: clinical insights from a narrative review of literature [J ] . Thyroid , 2023 , 33 ( 6 ): 674 - 681 .

BROSE M S , SMIT J , CAPDEVILA J , et al. Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma [J ] . Expert Rev Anticancer Ther , 2012 , 12 ( 9 ): 1137 - 1147 .

YAVUZ S , PUCKETT Y . Iodine-131 uptake study [M ] , StatPearls . Treasure Island : StatPearls Publishing , 2023 .

HOU P , BOJDANI E , XING M Z . Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways [J ] . J Clin Endocrinol Metab , 2010 , 95 ( 2 ): 820 - 828 . DOI: 10.1210/jc.2009-1888 http://doi.org/10.1210/jc.2009-1888

ZHANG Z J , LIU D X , MURUGAN A K , et al. Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer [J ] . Endocr Relat Cancer , 2014 , 21 ( 2 ): 161 - 173 .

NAGARAJAH J , LE M N , KNAUF J A , et al. Sustained ERK inhibition maximizes responses of Braf V600E thyroid cancers to radioiodine [J ] . J Clin Invest , 2016 , 126 ( 11 ): 4119 - 4124 .

LAHA D , NILUBOL N , BOUFRAQECH M . New therapies for advanced thyroid cancer [J ] . Front Endocrinol (Lausanne) , 2020 , 11 : 82 .

HAROON AL , RASHEED M R , XU B . Molecular alterations in thyroid carcinoma [J ] . Surg Pathol Clin , 2019 , 12 ( 4 ): 921 - 930 . DOI: S1875-9181(19)30058-3 http://doi.org/S1875-9181(19)30058-3

XING M Z . Identifying genetic alterations in poorly differentiated thyroid cancer: a rewarding pursuit [J ] . J Clin Endocrinol Metab , 2009 , 94 ( 12 ): 4661 - 4664 . DOI: 10.1210/jc.2009-2147 http://doi.org/10.1210/jc.2009-2147

MIZUKAMI T , SHIRAISHI K , SHIMADA Y , et al. Molecular mechanisms underlying oncogenic RET fusion in lung adenocarcinoma [J ] . J Thorac Oncol , 2014 , 9 ( 5 ): 622 - 630 .

YANG X , LI J , LI X Y , et al. TERT promoter mutation predicts radioiodine-refractory character in distant metastatic differentiated thyroid cancer [J ] . J Nucl Med , 2017 , 58 ( 2 ): 258 - 265 .

ARAQUE K A , GUBBI S , KLUBO-GWIEZDZINSKA J . Updates on the management of thyroid cancer [J ] . Horm Metab Res , 2020 , 52 ( 8 ): 562 - 577 . DOI: 10.1055/a-1089-7870 http://doi.org/10.1055/a-1089-7870

TUCCILLI C , BALDINI E , SORRENTI S , et al. CTLA-4 and PD-1 ligand gene expression in epithelial thyroid cancers [J ] . Int J Endocrinol , 2018 , 2018 : 1742951 .

CUNHA L L , MARCELLO M A , VASSALLO J , et al. Differentiated thyroid carcinomas and their B7H1 shield [J ] . Future Oncol , 2013 , 9 ( 10 ): 1417 - 1419 . DOI: 10.2217/fon.13.89 http://doi.org/10.2217/fon.13.89

AL-ABDALLAH A , JAHANBANI I , MEHDAWI H , et al. Down-regulation of the human major histocompatibility complex class Ⅰ chain-related gene A (MICA) and its receptor is mediated by microRNA-146b-5p and is a potential mechanism of immunoediting in papillary thyroid carcinoma [J ] . Exp Mol Pathol , 2020 , 113 : 104379 .

ULISSE S , TUCCILLI C , SORRENTI S , et al. PD-1 ligand expression in epithelial thyroid cancers: potential clinical implications [J ] . Int J Mol Sci , 2019 , 20 ( 6 ): 1405.

BASTOS A U , OLER G , NOZIMA B H N , et al. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma [J ] . Eur J Endocrinol , 2015 , 173 ( 4 ): 525 - 540 .

CORRADO A , FERRARI S M , POLITTI U , et al. Aggressive thyroid cancer: targeted therapy with sorafenib [J ] . Minerva Endocrinol , 2017 , 42 ( 1 ): 64 - 76 . DOI: 10.23736/S0391-1977.16.02229-X http://doi.org/10.23736/S0391-1977.16.02229-X

SHEN H Z , ZHU R , LIU Y Y , et al. Radioiodine-refractory differentiated thyroid cancer: molecular mechanisms and therapeutic strategies for radioiodine resistance [J ] . Drug Resist Updat , 2024 , 72 : 101013 .

BROSE M S , NUTTING C M , JARZAB B , et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial [J ] . Lancet , 2014 , 384 ( 9940 ): 319 - 328 . DOI: 10.1016/S0140-6736(14)60421-9 http://doi.org/10.1016/S0140-6736(14)60421-9

DACOSTA BYFIELD S A , ADEJORO O , COPHER R , et al. Real-world treatment patterns among patients initiating small molecule kinase inhibitor therapies for thyroid cancer in the United States [J ] . Adv Ther , 2019 , 36 ( 4 ): 896 - 915 . DOI: 10.1007/s12325-019-0890-6 http://doi.org/10.1007/s12325-019-0890-6

SILAGHI H , LOZOVANU V , GEORGESCU C E , et al. State of the art in the current management and future directions of targeted therapy for differentiated thyroid cancer [J ] . Int J Mol Sci , 2022 , 23 ( 7 ): 3470.

SCHLUMBERGER M , TAHARA M , WIRTH L J , et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer [J ] . N Engl J Med , 2015 , 372 ( 7 ): 621 - 630 .

ZHENG X Q , XU Z G , JI Q H , et al. A randomized, phase Ⅲ study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer [J ] . Clin Cancer Res , 2021 , 27 ( 20 ): 5502 - 5509 .

BROSE M S , ROBINSON B G , SHERMAN S I , et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial [J ] . Cancer , 2022 , 128 ( 24 ): 4203 - 4212 . DOI: 10.1002/cncr.34493 http://doi.org/10.1002/cncr.34493

CAPDEVILA J , KRAJEWSKA J , HERNANDO J , et al. Increased progression-free survival with cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer irrespective of prior vascular endothelial growth factor receptor-targeted therapy and tumor histology: a subgroup analysis of the COSMIC-311 study [J ] . Thyroid , 2024 , 34 ( 3 ): 347 - 359 .

CHI Y , ZHENG X Q , ZHANG Y , et al. Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: a randomized, double-blind, multicenter phase Ⅱ trial [J ] . Clin Cancer Res , 2023 , 29 ( 20 ): 4047 - 4056 .

李娇 , 韩娜 , 卢承慧 , 等 . 安罗替尼治疗远处转移性放射性碘难治性分化型甲状腺癌的有效性及安全性分析 [J ] . 中华核医学与分子影像杂志 , 2023 , 43 ( 8 ): 470 - 474 .

LI J , HAN N , LU C H , et al. Efficacy and safety analysis of anlotinib in the treatment of distant metastatic radioactive iodine-refractory differentiated thyroid cancer [J ] . Chin J Nucl Med Mol Imag , 2023 , 43 ( 8 ): 470 - 474 .

张芳蕾 , 翟红彦 , 闫瑞红 , 等 . 安罗替尼对进展期放射性碘难治性分化型甲状腺癌的疗效及对病灶摄碘功能的影响 [J ] . 中华核医学与分子影像杂志 , 2024 , 44 ( 10 ): 592 - 596 .

ZHANG F L , ZHAI H Y , YAN R H , et al. Efficacy of anlotinib in the treatment of advanced radioactive iodine-refractory differentiated thyroid cancer and the effect on iodine uptake of lesions [J ] . Chin J Nucl Med Mol Imag , 2024 , 44 ( 10 ): 592 - 596 .

LIU Y J , WANG J F , HU X P , et al. Radioiodine therapy in advanced differentiated thyroid cancer: resistance and overcoming strategy [J ] . Drug Resist Updat , 2023 , 68 : 100939 .

LIN Y S , YANG H , DING Y , et al. Donafenib in progressive locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer: results of a randomized, multicenter phase II trial [J ] . Thyroid , 2021 , 31 ( 4 ): 607 - 615 .

LIN Y S , QIN S K , YANG H , et al. Multicenter randomized double-blind phase Ⅲ trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer [J ] . Clin Cancer Res , 2023 , 29 ( 15 ): 2791 - 2799 .

LIN Y S , QIN S K , LI Z Y , et al. Apatinib vs placebo in patients with locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: the REALITY randomized clinical trial [J ] . JAMA Oncol , 2022 , 8 ( 2 ): 242 - 250 .

刘杰蕊 , 张鑫 , 孙郁青 , 等 . BRAF V600E突变辅助预测放射性碘难治性分化型甲状腺癌阿帕替尼治疗效果的意义 [J ] . 中华核医学与分子影像杂志 , 2023 , 43 ( 8 ): 465 - 469 .

LIU J R , ZHANG X , SUN Y Q , et al. Significance of BRAF V600E mutation in prediction of the efficacy of apatinib for radioactive iodine-refractory differentiated thyroid cancer\n [J ] . Chin J Nucl Med Mol Imag , 2023 , 43 ( 8 ): 465 - 469 .

QIU X , CHENG L , SA R , et al. Initial or salvage treatment with apatinib shows promise against radioiodine-refractory differentiated thyroid carcinoma [J ] . Eur Thyroid J , 2022 , 11 ( 2 ): e210065.

DUNN L A , SHERMAN E J , BAXI S S , et al. Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers [J ] . J Clin Endocrinol Metab , 2019 , 104 ( 5 ): 1417 - 1428 .

MICHAEL ROTHENBERG S , MCFADDEN D G , PALMER E L , et al. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib [J ] . Clin Cancer Res , 2015 , 21 ( 5 ): 1028 - 1035 .

HO A L , GREWAL R K , LEBOEUF R , et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer [J ] . N Engl J Med , 2013 , 368 ( 7 ): 623 - 632 .

BUSAIDY N L , KONDA B , WEI L , et al. Dabrafenib versus dabrafenib+trametinib in BRAF -mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial [J ] . Thyroid , 2022 , 32 ( 10 ): 1184 - 1192 .

SHI B , MA W B , PAN H S , et al. Cost-effectiveness of apatinib and cabozantinib for the treatment of radioiodine-refractory differentiated thyroid cancer [J ] . Front Pharmacol , 2022 , 13 : 860615 .

WANG X S , LI M Y . Correlate tumor mutation burden with immune signatures in human cancers [J ] . BMC Immunol , 2019 , 20 ( 1 ): 4.

PINHEIRO NETO A , LUCCHESI H L , VALSECCHI V A D S , et al. Immunotherapy for patients with thyroid cancer: a comprehensive appraisal [J ] . Chin Clin Oncol , 2024 , 13 ( 3 ): 36.

NIKIFOROV Y E , NIKIFOROVA M N . Molecular genetics and diagnosis of thyroid cancer [J ] . Nat Rev Endocrinol , 2011 , 7 ( 10 ): 569 - 580 . DOI: 10.1038/nrendo.2011.142 http://doi.org/10.1038/nrendo.2011.142

WANG S M , KHAN F I . Investigation of molecular interactions mechanism of pembrolizumab and PD-1 [J ] . Int J Mol Sci , 2023 , 24 ( 13 ): 10684.

MEHNERT J M , VARGA A , BROSE M S , et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer [J ] . BMC Cancer , 2019 , 19 ( 1 ): 196.

OH D Y , ALGAZI A , CAPDEVILA J , et al. Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study [J ] . Cancer , 2023 , 129 ( 8 ): 1195 - 1204 .

PAZ-ARES L , DVORKIN M , CHEN Y B , et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial [J ] . Lancet , 2019 , 394 ( 10212 ): 1929 - 1939 .

BURMAN B , SHERMAN E J , KRIPLANI A , et al. Radioiodine (RAI) in combination with durvalumab for recurrent/metastatic thyroid cancers [J ] . J Clin Oncol , 2020 , 38 ( 15_suppl ): 6587.

WÄCHTER S , KNAUFF F , ROTH S , et al. Synergic induction of autophagic cell death in anaplastic thyroid carcinoma [J ] . Cancer Invest , 2023 , 41 ( 4 ): 405 - 421 .

TABERNERO J , ANDRE F , BLAY J Y , et al. Phase Ⅱ multicohort study of atezolizumab monotherapy in multiple advanced solid cancers [J ] . ESMO Open , 2022 , 7 ( 2 ): 100419.

WANG Y C , ZHANG H , LIU C , et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts [J ] . J Hematol Oncol , 2022 , 15 ( 1 ): 1 11.

SAKAMURI D , GLITZA I C , BETANCOURT CUELLAR S L , et al. Phase I dose-escalation study of anti-CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers [J ] . Mol Cancer Ther , 2018 , 17 ( 3 ): 671 - 676 . DOI: 10.1158/1535-7163.MCT-17-0673 http://doi.org/10.1158/1535-7163.MCT-17-0673

BARBARI C , FONTAINE T , PARAJULI P , et al. Immunotherapies and combination strategies for immuno-oncology [J ] . Int J Mol Sci , 2020 , 21 ( 14 ): 5009.

LORCH J H , BARLETTA J A , NEHS M , et al. A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC) [J ] . J Clin Oncol , 2020 , 38 ( 15_suppl ): 6513.

SHENG X Y . Evaluation of safety and therapeutic efficacy of CAR-T therapy [J ] . Highlights Sci Eng Technol , 2024 , 91 : 272 - 276 .

LI H N , ZHOU X , WANG G , et al. CAR-T cells targeting TSHR demonstrate safety and potent preclinical activity against differentiated thyroid cancer [J ] . J Clin Endocrinol Metab , 2022 , 107 ( 4 ): 1110 - 1126 .

MIN I M , SHEVLIN E , VEDVYAS Y , et al. CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors [J ] . Clin Cancer Res , 2017 , 23 ( 24 ): 7569 - 7583 . DOI: 10.1158/1078-0432.CCR-17-2008 http://doi.org/10.1158/1078-0432.CCR-17-2008

HAUGEN B , FRENCH J , WORDEN F P , et al. Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): results of a multicenter phase Ⅱ International Thyroid Oncology Group trial [J ] . J Clin Oncol , 2020 , 38 ( 15_suppl ): 6512.

HAUGEN B , FRENCH J D , WORDEN F , et al. Pembrolizumab salvage add-on therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC) progressing on lenvatinib: results of a multicenter phase Ⅱ International Thyroid Oncology Group trial [J ] . Ann Oncol , 2020 , 31 : S1086 -S1087.

FRENCH J D , HAUGEN B R , WORDEN F P , et al. Combination targeted therapy with pembrolizumab and lenvatinib in progressive, radioiodine-refractory differentiated thyroid cancers [J ] . Clin Cancer Res , 2024 , 30 ( 17 ): 3757 - 3767 .

LI J Y , ZHANG X , MU Z Z , et al. Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: a case report and literature review [J ] . Front Immunol , 2022 , 13 : 943916 .

VANNEMAN M , DRANOFF G . Combining immunotherapy and targeted therapies in cancer treatment [J ] . Nat Rev Cancer , 2012 , 12 ( 4 ): 237 - 251 . DOI: 10.1038/nrc3237 http://doi.org/10.1038/nrc3237

ACKERMAN A , KLEIN O , MCDERMOTT D F , et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors [J ] . Cancer , 2014 , 120 ( 11 ): 1695 - 1701 . DOI: 10.1002/cncr.28620 http://doi.org/10.1002/cncr.28620

BONI A , COGDILL A P , DANG P , et al. Selective BRAF V600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function [J ] . Cancer Res , 2010 , 70 ( 13 ): 5213 - 5219 .

SUMIMOTO H , IMABAYASHI F , IWATA T , et al. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells [J ] . J Exp Med , 2006 , 203 ( 7 ): 1651 - 1656 . DOI: 10.1084/jem.20051848 http://doi.org/10.1084/jem.20051848

浏览量

1620

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

卡瑞利珠单抗联合化疗及靶向治疗在复发、转移及初治晚期宫颈癌中的疗效与安全性分析：一项回顾性队列研究

2022年中国乳腺癌重要临床试验成果及最新进展

靶向治疗及免疫治疗联合化疗为产AFP阳性结肠癌患者带来显著获益1例病例报告并文献复习

转移性结直肠癌三线治疗的研究现状及进展

恶性胸膜间皮瘤治疗的研究现状与展望